U.S.: Delaware lifts restrictions on who can qualify for hepatitis C treatment

Delaware is phasing out its restrictions on who can get newer, more effective hepatitis C treatments. The drugs are essentially a cure for a blood-borne disease that's a leading cause of liver failure in the United States. But the cost has put many states, including Delaware, in a fiscal bind. In 2014, Delaware spent nearly $2.5 million to treat 44 people; last year, it cost the state $13.5 million to treat 141 people. Stephen Groff, director of Del